View Older Stories

Mar 25, 2026 03:05PM Sarepta Therapeutics (SRPT) PT Raised to $25 at Morgan Stanley

Mar 25, 2026 03:02PM BofA Securities stays Underperform on Sarepta Therapeutics (SRPT): data update 'directionally positive'

Mar 25, 2026 10:46AM Mizuho on Sarepta Therapeutics (SRPT): data de-risks siRNA platform, supports BIC potential

Mar 25, 2026 10:43AM Wolfe Research stays Peerperform on Sarepta Therapeutics (SRPT) as data boosts RNA-focused narrative

Mar 25, 2026 10:33AM Leerink Partners on Sarepta Therapeutics (SRPT): siRNA data 'a bit of a mixed bag'

Mar 25, 2026 10:32AM Jefferies sees '+15-30% stock move' for Sarepta Therapeutics (SRPT) following data

Mar 25, 2026 08:05AM Sarepta shares early clinical data from siRNA treatments for rare diseases

Mar 19, 2026 11:11AM BofA Securities on Sarepta Therapeutics (SRPT): sNDAs 'positive first step' but regulatory risk continues

Mar 19, 2026 10:57AM Jefferies: Sarepta (SRPT) sNDA filings to set stage for 25% stock move on FDA decision

Mar 19, 2026 08:30AM Sarepta plans regulatory submissions for two Duchenne drugs by April 2026

Mar 17, 2026 07:37AM Cantor Fitzgerald Reiterates Neutral Rating on Sarepta Therapeutics (SRPT)

Mar 16, 2026 08:34AM Sarepta begins enrollment for enhanced safety protocol in gene therapy study

Mar 12, 2026 05:06PM Sarepta Therapeutics (SRPT) PT Raised to $31 at Mizuho

Mar 9, 2026 03:22PM Jefferies Reiterates Buy Rating on Sarepta Therapeutics (SRPT) following MDA conference 2026

Mar 3, 2026 03:44PM Sarepta Therapeutics (SRPT) PT Raised to $25 at Freedom Capital Markets

Mar 3, 2026 12:00PM Jefferies Reiterates Buy Rating on Sarepta Therapeutics (SRPT); cites as potential "recovery story"

Mar 2, 2026 06:47AM Sarepta Therapeutics (SRPT) PT Lowered to $29 at Wedbush

Feb 26, 2026 08:30AM Sarepta to present Duchenne muscular dystrophy data at 2026 MDA conference

Feb 25, 2026 04:45PM Sarepta Therapeutics (SRPT) Misses Q4 EPS by 237c

Feb 24, 2026 09:08AM Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan

Feb 4, 2026 08:30AM SAREPTA gets approval to test Huntington's disease treatment in humans

Jan 27, 2026 06:43AM JPMorgan on Sarepta Therapeutics (SRPT): 'Quick Thoughts On Elevidys 3-Year EMBARK Data'

Jan 26, 2026 12:54PM Sarepta Therapeutics (SRPT) PT Raised to $22 at Baird

Jan 26, 2026 08:01AM Sarepta reports positive three-year results for Duchenne gene therapy

Jan 26, 2026 05:30AM Sarepta Therapeutics (SRPT) call put ratio 1.7 calls to 1 put into presenting three-year results from its EMBARK study of ELEVIDYS

Jan 26, 2026 05:18AM RBC Capital on Sarepta (SRPT): 'KOL Feedback Suggests Elevidys Use Unlikely To Pick Back Up in '26'

Jan 23, 2026 04:05PM Sarepta to present 3-year ELEVIDYS gene therapy data on Jan. 26

Jan 14, 2026 06:55AM H.C. Wainwright Reiterates Sell Rating on Sarepta Therapeutics (SRPT)

Jan 14, 2026 04:39AM Mizuho Reiterates Outperform Rating on Sarepta Therapeutics (SRPT)

Jan 12, 2026 11:59AM Sarepta reports $1.86 billion in 2025 product revenue

Jan 12, 2026 09:30AM Johnson Fistel Investigates Sarepta Therapeutics, Inc. (SRPT) Directors for Potential Breaches of Fiduciary Duty

Jan 8, 2026 03:59AM Leerink Partners Reiterates Market Perform Rating on Sarepta Therapeutics (SRPT)

Jan 7, 2026 08:31AM Sarepta submits clinical trial application for Huntington's disease drug

Dec 11, 2025 11:53AM Mizuho on Sarepta Therapeutics (SRPT): 'See Today's Weakness as Buying Opportunity'

Dec 9, 2025 06:50AM Wedbush Starts Sarepta Therapeutics (SRPT) at Outperform

Nov 25, 2025 08:58AM Sarepta receives FDA approval for ELEVIDYS study with enhanced immunosuppression

Nov 25, 2025 07:31AM Sarepta Therapeutics (SRPT) PT Raised to $20 at Bernstein SocGen Group

Nov 24, 2025 07:31AM Sarepta advances SRP-1003 trial, triggers $200 million milestone payment

Nov 24, 2025 07:30AM Arrowhead Pharmaceuticals receives $200 million from Sarepta milestone

Nov 20, 2025 03:59AM Mizuho Reiterates Outperform Rating on Sarepta Therapeutics (SRPT)

Nov 14, 2025 02:59PM FDA approves updated ELEVIDYS label with liver injury warning

Nov 14, 2025 02:02PM FDA approves new safety warning and revised indication that limits use for Elevidys following reports of fatal liver injuryHHS: FDA approves new safety warning and revised indication that limits

Nov 5, 2025 10:07AM Mizuho upgrades Sarepta on confidence in Elevidys uptake

Nov 5, 2025 04:33AM Mizuho Upgrades Sarepta Therapeutics (SRPT) to Outperform

Nov 4, 2025 05:13AM Sarepta Therapeutics (SRPT) PT Lowered to $15 at Baird

Nov 3, 2025 04:41PM After-hours movers: Palantir, Hims & Hers Health, Sarepta Therapeutics, Sanmina

Nov 3, 2025 04:17PM Sarepta Therapeutics (SRPT) Tops Q3 EPS by 57c

Nov 3, 2025 04:13PM Sarepta completes confirmatory study for duchenne therapies, study misses primary endpoint

Oct 8, 2025 12:07PM Jefferies Reiterates Buy Rating on Sarepta Therapeutics (SRPT), 'Several Dynamics to Follow But Optics Could Further Improve in 2026'

Oct 7, 2025 06:37AM Mizuho Reiterates Neutral Rating on Sarepta Therapeutics (SRPT)

View Older Stories